Abstract
Digoxin toxicity usually arises due to increased dosing, impaired clearance, or interaction with other concomitant medications. Cardiac dysrhythmias may result, and the most effective treatment is the administration of digoxin-specific antibody. However, once the antibody is administered, renal clearance is required to eliminate the drug-antibody complex from the circulation. In patients with anuric renal failure, additional treatment modalities such as plasmapheresis may be needed to avoid recurrent toxicity once the antibody dissociates from the drug.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Bauman JL, Didomenico RJ, Galanter WL. Mechanisms, manifestations, and management of digoxin toxicity in the modern era. Am J Cardiovasc Drugs. 2006;6(2):77–86.
Critchley JA, Critchley LA. Digoxin toxicity in chronic renal failure; treatment by multiple dose activated charcoal intestinal dialysis. Hum Exp Toxicol. 1997;16:733–5.
Heatwole C, Johnson N, Holloway R, Noyes K. Plasma exchange vs. intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. J Clin Neuromuscul Dis. 2011;13(2):85–94.
Lexicomp. Digoxin Immune Fab. Pricing: US. 2015 Accessed 02 Sept 2015.
Rabetoy GM, et al. Treatment of digoxin intoxication in a renal failure patient with digoxin-specific antibody fragments and plasmapheresis. Am J Nephrol. 1990;10:518–21.
Renard C, Grene-Lerouge N, Beau N, Baud F, Scherrmann JM. Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age. Br J Clin Pharmacol. 1997;44(2):135–8.
Ujhelyi MR, Robert S, Cummings DM, Colucci RD, Green PJ, Sailstad J, et al. Influence of digoxin immune Fab therapy and renal dysfunction on the disposition of total and free digoxin. Ann Intern Med. 1993;119:273–7.
Zdunek M, Mitra A, Mokrzycki MH. Plasma exchange for the removal of digoxin-specific antibody fragments in renal failure: timing is important for maximizing clearance. Am J Kidney Dis. 2000;36(1):177–83.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Lopez, A. (2017). Case 24 Weakness in a Dialysis Patient. In: Dye, L.R., Murphy, C., Calello, D.P., Levine, M.D., Skolnik, A. (eds) Case Studies in Medical Toxicology. Springer, Cham. https://doi.org/10.1007/978-3-319-56449-4_24
Download citation
DOI: https://doi.org/10.1007/978-3-319-56449-4_24
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56447-0
Online ISBN: 978-3-319-56449-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)